NCT04935021RecruitingPhase 4
Clinical Study of ATTR-CM
Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers
Source: ClinicalTrials.gov · Last updated 31 Jan 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 20 Jun 2021
- Start date
- 1 Jun 2021
- Primary completion date
- 1 Jun 2031
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Amyloidosis
- NCT number
- NCT04935021
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 1 Jun 2021 to the primary completion date, 1 Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors
Who the study is looking for
- Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
- Patients who have the ability to understand the test and can cooperate with investigators
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| xiaohong University PAN Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.